Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $11.30, but opened at $10.81. Stoke Therapeutics shares last traded at $11.28, with a volume of 64,901 shares traded.
Wall Street Analysts Forecast Growth
STOK has been the subject of several research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital started coverage on Stoke Therapeutics in a report on Friday. They set a "buy" rating and a $24.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $21.29.
View Our Latest Research Report on Stoke Therapeutics
Stoke Therapeutics Trading Up 3.4 %
The stock has a market cap of $618.65 million, a PE ratio of -5.56 and a beta of 0.95. The company's 50 day moving average is $12.49 and its 200-day moving average is $13.58.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.
Insiders Place Their Bets
In other news, insider Barry Ticho sold 13,945 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the transaction, the insider now owns 47,332 shares of the company's stock, valued at approximately $604,902.96. This trade represents a 22.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares of the company's stock, valued at $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 in the last three months. 11.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Stoke Therapeutics
Institutional investors have recently made changes to their positions in the company. Lynx1 Capital Management LP lifted its holdings in Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the period. Logos Global Management LP bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth approximately $14,186,000. Marshall Wace LLP lifted its holdings in shares of Stoke Therapeutics by 550.1% in the 2nd quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock worth $15,686,000 after purchasing an additional 982,451 shares during the last quarter. Finally, RTW Investments LP boosted its position in Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock valued at $57,177,000 after purchasing an additional 427,447 shares during the period.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
